Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Randomized Study to Evaluate the Addition of Docetaxel (Taxotere) to the Combination of Cisplatin-5-Fluorouracil (TCF) vs. Cisplatin-5-Fluorouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma (NPC) in Children and Adolescents

Trial Profile

International Randomized Study to Evaluate the Addition of Docetaxel (Taxotere) to the Combination of Cisplatin-5-Fluorouracil (TCF) vs. Cisplatin-5-Fluorouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma (NPC) in Children and Adolescents

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Docetaxel (Primary) ; Cisplatin; Fluorouracil
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Jan 2012 Actual end date ( Jan 2012) added as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top